The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://tedwpmc468804.national-wiki.com/1989468/retatrutide_vs_tirzepatide_a_comparative_analysis